GlassScriptPhysician profile
Steven J Wagner
NPI 1396716866
$6,499.49
in general payments reported to CMS, 2019-2025
30 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $316 · 2021: $690 · 2022: $1,210 · 2023: $1,203 · 2024: $1,341 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.18 |
| Education | $127.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $828.76 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $585.89 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $516.07 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $438.35 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $411.46 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Akebia Therapeutics INC | $410.39 | 2019-2024 | Auryxia |
| Fresenius USA Marketing, INC. | $379.20 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $335.48 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $331.43 | 2021-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $271.39 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $232.15 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $227.42 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $219.62 | 2023-2025 | |
| Glaxosmithkline, LLC. | $218.28 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Ardelyx, INC. | $176.27 | 2023-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $145.07 | 2025 | Concertotm |
| Horizon Therapeutics Plc | $123.88 | 2019-2023 | Krystexxa |
| Vanda Pharmaceuticals INC. | $111.04 | 2021-2023 | Hetlioz, Fanapt |
| Alexion Pharmaceuticals, INC. | $109.03 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $87.25 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.68 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $50.88 | 2023-2025 | Jardiance |
| Baxter Healthcare | $41.51 | 2022-2023 | Renal - Acute |
| Daiichi Sankyo INC. | $38.53 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $35.62 | 2023-2024 | Cystadrops, Panhematin |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2024 | Livtencity |
| Nxstage Medical, INC. | $25.74 | 2025 | Nxstage Pureflow Solution, Nxstage Cartridge Express, Nxstage System One |
| Mallinckrodt Enterprises LLC | $19.21 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.80 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.49 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.